Ingiridur Skirnisdottir1, Helena Akerud2, Tomas Seidal3, Inger Sundstrom-Poromaa4. 1. Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden ingiridur.skirnisdottir@kbh.uu.se. 2. Department of Immunology, Genetics and Pathology Uppsala University, Uppsala, Sweden. 3. Department of Pathology, Halmstad Medical Center Hospital, Halmstad, Sweden. 4. Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
Abstract
BACKGROUND/AIM: The aim of the present study was to evaluate the association between body mass index (BMI), the biomarker p27, and the clinical factors in FIGO-stages I-II ovarian cancer. PATIENTS AND METHODS: A total of 128 patients with ovarian cancer were included in the study. For testing differences in univariate analyzes we used the Pearson's Chi-square test and the log-rank test. For multivariate analyses the logistic regression and Cox regression models were used with recurrent disease and disease-free survival as endpoints, respectively. RESULTS: Patients with BMI ≤25 kg/m2 had a significantly better 5-year disease-free survival compared with patients with BMI >25 kg/m2 in the total series of patients (p=0.008), and in the series of patients (n=77) with non-serous tumors (p=0.047). Patients with p27-positive non-serous tumors had higher survival compared to patients with p27-negative non-serous tumors (p=0.020). CONCLUSION: The cell cycle regulator p27 mediates BMI effects in ovarian cancer in FIGO-stages I-II. Copyright
BACKGROUND/AIM: The aim of the present study was to evaluate the association between body mass index (BMI), the biomarker p27, and the clinical factors in FIGO-stages I-II ovarian cancer. PATIENTS AND METHODS: A total of 128 patients with ovarian cancer were included in the study. For testing differences in univariate analyzes we used the Pearson's Chi-square test and the log-rank test. For multivariate analyses the logistic regression and Cox regression models were used with recurrent disease and disease-free survival as endpoints, respectively. RESULTS:Patients with BMI ≤25 kg/m2 had a significantly better 5-year disease-free survival compared with patients with BMI >25 kg/m2 in the total series of patients (p=0.008), and in the series of patients (n=77) with non-serous tumors (p=0.047). Patients with p27-positive non-serous tumors had higher survival compared to patients with p27-negative non-serous tumors (p=0.020). CONCLUSION: The cell cycle regulator p27 mediates BMI effects in ovarian cancer in FIGO-stages I-II. Copyright
Authors: Shuji Ogino; Kaori Shima; Katsuhiko Nosho; Natsumi Irahara; Yoshifumi Baba; Brian M Wolpin; Edward L Giovannucci; Jeffrey A Meyerhardt; Charles S Fuchs Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-06 Impact factor: 4.254
Authors: J Kononen; L Bubendorf; A Kallioniemi; M Bärlund; P Schraml; S Leighton; J Torhorst; M J Mihatsch; G Sauter; O P Kallioniemi Journal: Nat Med Date: 1998-07 Impact factor: 53.440
Authors: Elisa V Bandera; Valerie S Lee; Bo Qin; Lorna Rodriguez-Rodriguez; C Bethan Powell; Lawrence H Kushi Journal: Br J Cancer Date: 2017-06-06 Impact factor: 7.640